Aims And Methods: This study assessed incidence, predictive factors, and outcome of Epstein-Barr virus (EBV) DNAemia in 100 recipients of allogeneic hematopoietic stem cell transplant. A total of 68 patients received anti-thymocyte globulin before unrelated grafts.
Results: Cumulative incidence of high-load EBV DNAemia defined by levels >10,000 copies/mL was 14% at 12 months. In multivariate analysis, a CD4+ T-lymphocyte count >50 μL at day +30 was the only factor significantly associated with a reduced risk of high-load EBV DNAemia. Thirteen of 16 patients with high viral loads were preemptively treated with rituximab and achieved EBV DNA negativity. Three patients had already developed post-transplant lymphoproliferative disorder (PTLD) at the time of detection of high EBV DNA loads, and they obtained complete response after rituximab infusions and chemotherapy. Patients with high EBV DNA load had a significantly higher transplant-related mortality (TRM) compared with patients with negative or low viral load (54% vs. 16%, P = 0.009) and a trend to lower overall survival (55% vs. 29%, P = 0.060).
Conclusion: We conclude that CD4+ cell count at day +30 is a predictive factor for EBV DNAemia and may help identify patients requiring closer monitoring. Although only 3% of patients progressed to PTLD and were all successfully managed, EBV reactivation was associated with higher TRM, mainly because of infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tid.12061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Limited utility of Epstein-Barr virus (EBV) surveillance for predicting post-transplant lymphoproliferative disorders in adult EBV seropositive lung transplant recipients.
J Clin Virol
December 2024
Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA. Electronic address:
Article Synopsis
- EBV DNAemia surveillance is used to prevent post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTRs), but its effectiveness in adult seropositive patients is unclear.
- A study analyzed EBV viral loads in seropositive LTRs and compared levels between those who developed PTLD and those who didn't, revealing that peak viral loads were only significantly higher after PTLD was suspected.
- The study found low positive predictive values (PPVs) for moderate (14.7%) and high-grade (33.3%) EBV DNAemia in indicating risk for future PTLD, suggesting improved diagnostic approaches are needed.
Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience.
Am J Clin Pathol
October 2024
Transplant and Immunocompromised Host Infectious Diseases, Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, US.
Objectives: Epstein-Barr virus (EBV) causes different clinical presentations in immunocompetent and immunocompromised persons, and thus indications for testing vary between these populations. We reviewed our institution's EBV DNA testing across these populations to understand its clinical utility and appropriateness.
Methods: We conducted a retrospective chart review of adult patients with positive EBV nucleic acid amplification (NAAT) testing from November 2022 to 2023.
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation.
J Hematol Oncol
October 2024
National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Article Synopsis
- Letermovir (LTV) prophylaxis significantly reduces the incidence of clinically significant cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- A study of 230 patients показал that those receiving LTV experienced a higher rate of Epstein-Barr virus (EBV) reactivation (27%) compared to those who did not receive LTV (13%).
- Despite the increased EBV reactivation, there were no major differences in recovery metrics, overall survival, or other complications between the LTV and control groups, suggesting a possible link between LTV use and increased EBV reactivation post-transplant.
Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.
Pediatr Nephrol
October 2024
Technion Faculty of Medicine, Haifa, Israel.
Article Synopsis
- Post-transplant lymphoproliferative disorder (PTLD) often occurs in patients who have undergone organ or stem cell transplants and is linked to Epstein-Barr virus (EBV) infection, which precedes PTLD in 90% of cases.
- A study involved pediatric kidney transplant recipients (PKTR) who were monitored for EBV through blood tests, and those with rising viral loads despite lowering immunosuppressive drugs were given preventive rituximab therapy.
- Results showed that rituximab was effective in clearing EBV from patients who struggled to respond to other treatments, suggesting that it may be a safe option for preventing PTLD in high-risk pediatric kidney transplant patients.
Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center.
J Med Virol
June 2024
Division of Gastroenterology, Hepatology, and Nutrition Disease, Department of Pediatrics, Medical School of Ege University, İzmir, Türkiye.
Article Synopsis
- Post-transplant lymphoproliferative disorder (PTLD) is a serious complication that can occur after solid organ transplants, particularly in pediatric liver transplant recipients.
- A study conducted on 112 pediatric patients revealed that 43.75% developed Epstein-Barr virus (EBV) DNAemia, with 8 of these patients subsequently diagnosed with PTLD.
- Findings showed that age at diagnosis of EBV DNAemia, as well as abnormal test results, were significantly higher in PTLD patients, indicating a correlation between older age and the development of this complication.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!